{"generic":"Umeclidinium Bromide\/Vilanterol Trifenatate","drugs":["Anoro Ellipta","Umeclidinium Bromide\/Vilanterol Trifenatate"],"mono":{"0":{"id":"930853-s-0","title":"Generic Names","mono":"Umeclidinium Bromide\/Vilanterol Trifenatate"},"1":{"id":"930853-s-1","title":"Dosing and Indications","sub":[{"id":"930853-s-1-4","title":"Adult Dosing","mono":"<b>Chronic obstructive pulmonary disease:<\/b> 1 ORAL INHALATION of umeclidinium bromide 62.5 mcg\/vilanterol trifenatate 25 mcg once daily; MAX 1 dose every 24 hours "},{"id":"930853-s-1-5","title":"Pediatric Dosing","mono":"efficacy and safety not established in pediatric patients "},{"id":"930853-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>geriatric:<\/b> no dose adjustment required<\/li><li><b>hepatic impairment, moderate:<\/b> no dose adjustment required<\/li><li><b>renal impairment:<\/b> no dose adjustment required<\/li><\/ul>"},{"id":"930853-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Chronic obstructive pulmonary disease<br\/>"}]},"2":{"id":"930853-s-2","title":"Black Box Warning","mono":"<b>Inhalation (Powder)<\/b><br\/>Asthma-related death: Long-acting beta(2)-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US trial that compared the safety of another LABA (salmeterol) with placebo added to the usual asthma therapy showed an increase in asthma-related deaths in subjects receiving salmeterol. This finding with salmeterol is considered a class effect of all LABA, including vilanterol, one of the active ingredients in the umeclidinium\/vilanterol combination. The safety and efficacy of umeclidinium\/vilanterol in patients with asthma have not been established. Umeclidinium\/vilanterol is not indicated for the treatment of asthma.<br\/>"},"3":{"id":"930853-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930853-s-3-9","title":"Contraindications","mono":"hypersensitivity, severe, to milk proteins, or hypersensitivity to umeclidinium, vilanterol, or any component of the product <br\/>"},{"id":"930853-s-3-10","title":"Precautions","mono":"<ul><li>asthma (unapproved use); increased risk of asthma-related death may occur with long-acting beta(2)-adrenergic agonists, including umeclidinium\/vilanterol<\/li><li>acute symptom relief (ie, rescue therapy for acute bronchospasm); use not recommended; not studied<\/li><li>cardiovascular disorders (eg, coronary insufficiency, cardiac arrhythmias, hypertension); increased risk for cardiovascular effects and ECG changes<\/li><li>cardiovascular effects, clinically significant (eg, increased pulse rate, systolic or diastolic blood pressure, or symptoms) may occur; discontinue use if occurs<\/li><li>concomitant, regular (eg, 4 times\/day) use of short-acting beta(2)-agonists; avoid use<\/li><li>concomitant use of anticholinergic-containing drugs; avoid use<\/li><li>concomitant use of beta-blockers; normally not recommended; consider cardioselective beta-blockers if no alternatives exist<\/li><li>concomitant use of long-acting beta(2)-agonists (eg, salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol); avoid use<\/li><li>convulsive disorders or thryrotoxicosis; contains sympathomimetic amines<\/li><li>deteriorating COPD, acute, or potentially life-threatening; use not recommended; not studied<\/li><li>diabetes mellitus and ketoacidosis; exacerbation has been reported IV doses of related beta-agonist, albuterol<\/li><li>ECG changes (eg, QTc prolongation, flattening of T wave, ST depression) have been reported with beta-agonists<\/li><li>higher than recommended doses or use more frequently than recommended (once per 24 hours); avoid use<\/li><li>hypersensitivity reactions may occur<\/li><li>hypokalemia, significant, may occur and result in cardiovascular effects<\/li><li>hyperglycemia, transient, may occur<\/li><li>narrow-angle glaucoma; worsening may occur; monitoring recommended<\/li><li>paradoxical bronchospasm, potentially life-threatening, may occur; discontinue use immediately if occurs<\/li><li>responsiveness to sympathomimetic amines, unusual; contains sympathomimetic amines<\/li><li>urinary retention (eg, prostatic hyperplasia, bladder neck obstruction); exacerbation of symptoms may occur; monitoring recommended<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930853-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930853-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930853-s-4","title":"Drug Interactions","sub":[{"id":"930853-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Nelfinavir (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"930853-s-4-14","title":"Major","mono":"<ul><li>Acebutolol (theoretical)<\/li><li>Alfuzosin (theoretical)<\/li><li>Amineptine (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amitriptylinoxide (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Atenolol (theoretical)<\/li><li>Atropine (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Befunolol (theoretical)<\/li><li>Belladonna (theoretical)<\/li><li>Benztropine (theoretical)<\/li><li>Betaxolol (theoretical)<\/li><li>Bevantolol (theoretical)<\/li><li>Biperiden (theoretical)<\/li><li>Bisoprolol (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Bopindolol (theoretical)<\/li><li>Brompheniramine (theoretical)<\/li><li>Bupropion (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Butriptyline (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Carbinoxamine (theoretical)<\/li><li>Carisoprodol (theoretical)<\/li><li>Carteolol (theoretical)<\/li><li>Carvedilol (theoretical)<\/li><li>Celiprolol (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Chlorpheniramine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clemastine (theoretical)<\/li><li>Clidinium (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Cyclopentolate (theoretical)<\/li><li>Cyproheptadine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darifenacin (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Dibenzepin (theoretical)<\/li><li>Dicyclomine (theoretical)<\/li><li>Dimenhydrinate (theoretical)<\/li><li>Diphenhydramine (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Dothiepin (theoretical)<\/li><li>Doxepin (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Ebastine (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Esmolol (theoretical)<\/li><li>Fesoterodine (theoretical)<\/li><li>Flavoxate (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluphenazine (theoretical)<\/li><li>Furazolidone (probable)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Glycopyrrolate (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Homatropine (theoretical)<\/li><li>Hydroquinidine (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Hydroxyzine (theoretical)<\/li><li>Hyoscyamine (theoretical)<\/li><li>Ibutilide (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Ipratropium (theoretical)<\/li><li>Iprindole (theoretical)<\/li><li>Iproniazid (probable)<\/li><li>Isocarboxazid (probable)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Labetalol (theoretical)<\/li><li>Landiolol (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levobunolol (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Linezolid (probable)<\/li><li>Lofepramine (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Loratadine (theoretical)<\/li><li>Loxapine (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Meclizine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Melitracen (theoretical)<\/li><li>Mepenzolate (theoretical)<\/li><li>Mepindolol (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Methylene Blue (probable)<\/li><li>Metipranolol (theoretical)<\/li><li>Metoprolol (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Mizolastine (theoretical)<\/li><li>Moclobemide (probable)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nadolol (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nebivolol (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nipradilol (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Opipramol (theoretical)<\/li><li>Orphenadrine (theoretical)<\/li><li>Oxitropium Bromide (theoretical)<\/li><li>Oxprenolol (theoretical)<\/li><li>Oxybutynin (theoretical)<\/li><li>Oxymorphone (probable)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Pargyline (probable)<\/li><li>Paroxetine (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Penbutolol (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Perphenazine (theoretical)<\/li><li>Phenelzine (probable)<\/li><li>Pindolol (theoretical)<\/li><li>Pipenzolate Bromide (theoretical)<\/li><li>Pirenzepine (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Procarbazine (probable)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Procyclidine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Propantheline (theoretical)<\/li><li>Propiverine (theoretical)<\/li><li>Propizepine (theoretical)<\/li><li>Propranolol (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rasagiline (probable)<\/li><li>Ritonavir (theoretical)<\/li><li>Scopolamine (theoretical)<\/li><li>Selegiline (probable)<\/li><li>Sertindole (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Stramonium (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Talinolol (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Terodiline (theoretical)<\/li><li>Tertatolol (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Thiothixene (theoretical)<\/li><li>Tianeptine (theoretical)<\/li><li>Timolol (theoretical)<\/li><li>Tiotropium (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolterodine (theoretical)<\/li><li>Tranylcypromine (probable)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trihexyphenidyl (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Troleandomycin (theoretical)<\/li><li>Tropicamide (theoretical)<\/li><li>Trospium (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><\/ul>"}]},"5":{"id":"930853-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Chest pain (1%)<\/li><li><b>Gastrointestinal:<\/b>Constipation (1%), Diarrhea (2%)<\/li><li><b>Musculoskeletal:<\/b>Neck pain (1%), Pain in limb (2%), Spasm (1%)<\/li><li><b>Respiratory:<\/b>Lower respiratory tract infection (1%), Pharyngitis (2%), Sinusitis (1% or greater)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Atrial fibrillation (less than 1%), Increased heart rate, Myocardial infarction (less than 1%), Prolonged QT interval<\/li><li><b>Respiratory:<\/b>Paradoxical bronchospasm<\/li><\/ul>"},"6":{"id":"930853-s-6","title":"Drug Name Info","sub":{"0":{"id":"930853-s-6-17","title":"US Trade Names","mono":"Anoro Ellipta<br\/>"},"2":{"id":"930853-s-6-19","title":"Class","mono":"<ul><li>Antimuscarinic<\/li><li>Beta-2 Adrenergic Agonist<\/li><li>Respiratory Agent<\/li><\/ul>"},"3":{"id":"930853-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930853-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930853-s-7","title":"Mechanism Of Action","mono":"<ul><li>Umeclidinium is a long-acting anticholinergic agent which reversibly inhibits the M3 receptor at the smooth muscle, leading to bronchodilation.<\/li><li>Vilanterol is a long-acting beta(2)-adrenergic agonist. It stimulates adenyl cyclase resulting in increased intracellular cyclic AMP level which in turn triggers bronchial smooth muscles relaxation. The release of mediators for immediate hypersensitivity is also inhibited.<\/li><\/ul>"},"8":{"id":"930853-s-8","title":"Pharmacokinetics","sub":[{"id":"930853-s-8-23","title":"Absorption","mono":"Tmax, Inhalation: 5 to 15 minutes (umeclidinium and vilanterol) <br\/>"},{"id":"930853-s-8-24","title":"Distribution","mono":"<ul><li>Umeclidinium, protein binding: 89%<\/li><li>Umeclidinium, Vd: 86 L<\/li><li>Vilanterol, protein binding: 94%<\/li><li>Vilanterol, Vd: 165 L<\/li><\/ul>"},{"id":"930853-s-8-25","title":"Metabolism","mono":"<ul><li>Umeclidinium, Liver: extensive<\/li><li>Umeclidinium, substrate of CYP2D6 and P-glycoprotein<\/li><li>Vilanterol, Liver: extensive<\/li><li>Vilanterol, substrate of CYP3A4 and P-glycoprotein<\/li><\/ul>"},{"id":"930853-s-8-26","title":"Excretion","mono":"<ul><li>Umeclidinium, Bile: excreted (IV)<\/li><li>Umeclidinium, Fecal: 58% (IV); 92% (oral)<\/li><li>Umeclidinium, Renal excretion: 22% (IV); less than 1% (oral)<\/li><li>Vilanterol, Fecal: 30% (oral)<\/li><li>Vilanterol, Renal excretion: 70% (oral)<\/li><\/ul>"},{"id":"930853-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Umeclidinium, 11 hours<\/li><li>Vilanterol, 11 hours<\/li><\/ul>"}]},"9":{"id":"930853-s-9","title":"Administration","mono":"<b>Inhalation, oral<\/b><br\/><ul><li>administer at the same time every day<\/li><li>do not open the cover until ready to use<\/li><li>exhale fully before taking one long, steady, deep breath through the mouthpiece<\/li><li>hold breath for 3 to 4 seconds and exhale slowly and gently<\/li><\/ul>"},"10":{"id":"930853-s-10","title":"Monitoring","mono":"<ul><li>improvement or maintenance of respiratory function in patients with COPD may indicate efficacy<\/li><li>respiratory function, in patients with signs or symptoms suggestive of deterioration of disease<\/li><\/ul>"},"11":{"id":"930853-s-11","title":"How Supplied","mono":"<b>Anoro Ellipta<\/b><br\/>Inhalation Powder: (Umeclidinium Bromide - Vilanterol Trifenatate) 62.5 MCG\/Actuation-25 MCG\/Actuation<br\/>"},"13":{"id":"930853-s-13","title":"Clinical Teaching","mono":"<ul><li>Side effects may include pharyngitis, sinusitis, lower respiratory tract infection, constipation, diarrhea, pain in extremity, muscle spasms, neck pain, and chest pain.<\/li><li>Instruct patient to seek immediate medical attention if their symptoms get worse or if they need more inhalations from their rescue inhaler than usual.<\/li><li>Advise patient to report any symptoms of paradoxical bronchospasm.<\/li><li>Instruct patient to report signs\/symptoms of cardiovascular effects (eg, palpitations, chest pain, rapid heart rate, tremor, or nervousness).<\/li><li>Advise patient to report signs\/symptoms of acute narrow-angle glaucoma (eg, eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema).<\/li><li>Instruct patient to report signs\/symptoms of urinary retention (eg, difficulty passing urine, painful urination).<\/li><li>Instruct patient to take drug at the same time every day and not use it more than once every 24 hours.<\/li><li>Advise patient on proper preparation of the delivery device, and inhalation technique.<\/li><li>Advise patient that drug is not to be used to relieve acute symptoms and extra doses should not be used for that purpose. Instruct patient to treat acute symptoms with a rescue inhaler. For patients who have been using inhaled, short-acting beta(2)-agonists on a regular basis, tell them to discontinue the regular use of these products and use them only for relief of acute symptoms.<\/li><li>Advise patient that there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs.).<\/li><\/ul>"}}}